Labopharm Inc

DDS-T

Broke through the 200-day moving average at about $1.50. Looks like the momentum may start to peter out but there is some pretty good support around $1.40. If her broke that, you should Sell.

Has disappointed everyone for a long time. Didn't get approval on their product. Stock has been decimated. Thinks the worst is over, but it will be a long recovery. He was actually Short the stock for a while. If you own, Hold and see what they do, but don't be a buyer.

Has been a major disappointment. Guided that approvals would be fairly easy to receive, which didn't happen. Trials have been okay, not all that inclusive, so there is a lot of uncertainty.

Has been doing fairly well recently because they had their European and Canadian approval for their painkiller. Once they get the US of the way, it should be back over the $7 mark.

It is a small stock. Believes it will be a winner.

Entering into a licensing/distribution agreement with Purdue Pharma in the US. Did a disatrous financing last year and the stock sold off. This deal was a rabbit pulled out of a hat. The stock will probably flatline for a bit after this deal. Best to see quarter after quarter how revenues kick in.

Received approval in France for its drug tramadol. Has stubbed its toes many times with investors. Large outstanding stock holding (40 Million?) could come out and flood the market.

Drug companies in general scare value investors. Drugs they produce might injure or kill people. Also there's a history of companies suing each other because of infringement on property rights which can tie up a small company like this. Although they got French approval, FDA could be a whole different matter.

Management is at its risk. If they start in Europe, the stock will improve. Therefore, be cautious.

Did an issue and it was a disaster. Hasn't even come close to where the issue was priced at. Behind schedule as compared to their competitors.

Still suffering from a plethora of disappointments from late 2001 and 2002. Will have a challenge moving up from where it is. Prefers others.

Volatile. Too few projects on the go. Risky.

Interesting technology. Future is unclear. Risky.

(Was a top pick on Dec 18 down 46%) Still likes. Got hit with the pull out of Aventis, but should be able to get new deals over the next 6 months. Don't buy until they do strike a deal.

Speculative and risky. In a competitive sector.